Overview

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is: - To find out how safe the study drug, pembrolizumab, is when combined with stereotactic body radiotherapy (SBRT) to the liver. - To see how well subjects can tolerate treatment with pembrolizumab and SBRT. - To find out how often colorectal cancer comes back 1 year after surgically removing all known disease and being treated with SBRT and pembrolizumab.

Phase:

Phase 1

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborators:

Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)

Treatments:

Pembrolizumab